Onconephrology: The latest frontier in the war against kidney disease

Journal of the American Society of Nephrology

Volumn 24, Issue 1, 2013, Pages 26-30

  Salahudeen, Abdulla K ^a   Bonventre, Joseph V ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN INHIBITOR; CETUXIMAB; CIDOFOVIR; COLISTIN; CREATININE; IFOSFAMIDE; MAGNESIUM; METHOTREXATE; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; VASCULOTROPIN INHIBITOR;

ACUTE KIDNEY FAILURE; ARTICLE; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER THERAPY; CHRONIC KIDNEY DISEASE; CONTINUOUS RENAL REPLACEMENT THERAPY; CREATININE BLOOD LEVEL; DIALYSIS; DIARRHEA; ELECTROLYTE DISTURBANCE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOMAGNESEMIA; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY FUNCTION; MEDICAL PRACTICE; MEDICAL SOCIETY; NAUSEA; NEPHRECTOMY; NEPHROLOGIST; NEPHROTOXICITY; PATIENT CARE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SURVIVAL RATE; VOMITING;

EID: 84871895090     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012070690     Document Type: Article

References (40)

1. Schwartz WB, Bennett W, Curelop S, Bartter FC: A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 23: 529-542, 1957
2. Rieselbach RE, Bentzel CJ, Cotlove E, Frei E 3rd, Freireich EJ: Uric acid excretion and renal function in the acute hyperuricemia of leukemia. Pathogenesis and therapy of uric acid nephropathy. Am J Med 37: 872-883, 1964
3. Perazella MA, Moeckel GW: Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol 30: 570-581, 2010
4. Salahudeen AK, Doshi S, Pawar T, Gul N, Lahoti A, Shah P: Incidence rate, clinical correlates and outcomes of acute kidney injury in patients admitted to a comprehensive cancer center. Clin J Am Soc Neph 2013, in press
5. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, Martin PJ, Sandmaier BM, Marr KA, Appelbaum FR, Storb R, McDonald GB: Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363: 2091-2101, 2010
6. Robinson ES, Matulonis UA, Ivy P, Berlin ST, Tyburski K, Penson RT, Humphreys BD: Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol 5: 477-483, 2010
7. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358: 1129-1136, 2008 (Pubitemid 351398487)
8. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672-683, 2004 (Pubitemid 38364626)
9. Rajkumar SV: Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 86: 57-65, 2011
10. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M: Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: Long-term results in a series of 421 patients. Blood 118: 4346-4352, 2011
11. Christiansen CF, Johansen MB, Langeberg WJ, Fryzek JP, Sørensen HT: Incidence of acute kidney injury in cancer patients: A Danish population-based cohort study. Eur J Intern Med 22: 399-406, 2011
12. Samuels J, Ng CS, Nates J, Price K, Finkel K, Salahudeen A, Shaw A: Small increases in serum creatinine are associated with prolonged ICU stay and increased hospital mortality in critically ill patients with cancer. Support Care Cancer 19: 1527-1532, 2011
13. Lahoti A, Kantarjian H, Salahudeen AK, Ravandi F, Cortes JE, Faderl S, O'Brien S, Wierda W, Mattiuzzi GN: Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer 116: 4063-4068, 2010
14. Soares M, Salluh JI, Carvalho MS, Darmon M, Rocco JR, Spector N: Prognosis of critically ill patients with cancer and acute renal dysfunction. J Clin Oncol 24: 4003-4010, 2006 (Pubitemid 46630751)
15. Salahudeen AK, Kumar V, Madan N, Xiao L, Lahoti A, Samuels J, Nates J, Price K: Sustained low efficiency dialysis in the continuous mode (C-SLED):Dialysis ef ficacy, clinical outcomes, and survival predictors in critically ill cancer patients. Clin J Am Soc Nephrol 4: 1338-1346, 2009
16. Humphreys BD, Soiffer RJ, Magee CC: Renal failure associated with cancer and its treatment: An update. J Am Soc Nephrol 16: 151-161, 2005 (Pubitemid 43073167)
17. Zager RA: Acute renal failure in the setting of bone marrow transplantation. Kidney Int 46: 1443-1458, 1994
18. Parikh CR, Coca SG: Acute renal failure in hematopoietic cell transplantation. Kidney Int 69: 430-435, 2006 (Pubitemid 43164432)
19. Heher EC, Spitzer TR: Hematopoietic stem cell transplantation in patients with chronic kidney disease. Semin Nephrol 30: 602-614, 2010
20. Candrilli S, Bell T, Irish W, Morris E, Goldman S, Cairo MS: A comparison of inpatient length of stay and costs among patients with hematologicmalignancies (excludinghodgkin disease) associated with and without acute renal failure. Clin Lymphoma Myeloma 8: 44-51, 2008 (Pubitemid 351449718)
21. Launay-Vacher V: Epidemiology of chronic kidney disease in cancer patients: Lessons from the IRMA study group. Semin Nephrol 30: 548-556, 2010
22. Vaidya VS, Ozer JS, Dieterle F, Collings FB, Ramirez V, Troth S, Muniappa N, Thudium D, Gerhold D, Holder DJ, Bobadilla NA, Marrer E, Perentes E, Cordier A, Vonderscher J, Maurer G, Goering PL, Sistare FD, Bonventre JV: Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker quali fication studies. Nat Biotechnol 28: 478-485, 2010
23. Finkel KW, Foringer JR: Renal disease in patients with cancer. Nat Clin Pract Nephrol 3: 669-678, 2007 (Pubitemid 350146950)
24. Surveillance, Epidemiology, and End Results Program. SEER Cancer Statistics Review 1975-2009. 2012. Available at: http://seer.cancer.gov/csr/ 1975-2009-pops09/index.html. Accessed July 24, 2012
25. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW: Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16: 3365-3370, 2005 (Pubitemid 46179340)
26. Darmon M, Thiery G, Ciroldi M, Porcher R, Schlemmer B, Azoulay E: Should dialysis be offered to cancer patients with acute kidney injury? Intensive Care Med 33: 765-772, 2007 (Pubitemid 46675318)
27. Cho A, Lee JE, Kwon GY, Huh W, Lee HM, Kim YG, Kim DJ, Oh HY, Choi HY: Postoperative acute kidney injury in patients with renal cell carcinoma is a potent risk factor for new-onset chronic kidney disease after radical nephrectomy. Nephrol Dial Transplant 26: 3496-3501, 2011
28. Hingorani SR, Seidel K, Lindner A, Aneja T, Schoch G, McDonald G: Albuminuria in hematopoietic cell transplantation patients: prevalence, clinical associations, and impact on survival. Biol Blood Marrow Transplant 14: 1365-1372, 2008
29. Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V: Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 21: 1395-1403, 2010
30. Boesler B, Czock D, Keller F, Griesshammer M, Seufferlein T, Karges W, Rasche FM: Clinical course of haemodialysis patients with malignancies and dose-adjusted chemotherapy. Nephrol Dial Transplant 20: 1187-1191, 2005 (Pubitemid 40862109)
31. Holley JL: Screening, diagnosis, and treatment of cancer in long-term dialysis patients. Clin J Am Soc Nephrol 2: 604-610, 2007
32. Doshi SM, Shah P, Lei X, Lahoti A, Salahudeen AK: Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis 59: 222-228, 2012
33. Song S, Shi R, Li B, Liu Y: Diagnosis and treatment of pancreatic vasoactive intestinal peptide endocrine tumors. Pancreas 38: 811-814, 2009
34. Lacy MQ, Gertz MA: Acquired Fanconi's syndrome associated with monoclonal gammopathies. Hematol Oncol Clin North Am 13: 1273-1280, 1999 (Pubitemid 30017400)
35. Izzedine H, Bahleda R, Khayat D, Massard C, Magné N, Spano JP, Soria JC: Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol 73: 213-219, 2010
36. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S: Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: Systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf 11[Suppl 1]: S9-S19, 2012
37. Ouwerkerk J, Boers-Doets C: Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Eur J Oncol Nurs 14: 337-349, 2010
38. Clines GA: Mechanisms and treatment of hypercalcemia of malignancy. Curr Opin Endocrinol Diabetes Obes 18: 339-346, 2011
39. Pugliese G: Mediators of bone resorption and hypercalcemia in cancer. N Engl J Med 318: 642-643, 1988
40. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D'Agati VD: Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64: 281-289, 2003 (Pubitemid 36714182)